Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Tristel (TSTL) Competitors

Tristel logo
GBX 407.75 +8.87 (+2.22%)
As of 04:48 AM Eastern
Compare

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

Should you buy Tristel stock or one of its competitors? Tristel's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£233.63M2.64£11.22M£1.65171.52
Tristel£51.12M3.75£6.54M£16.2424.56

21.5% of Advanced Medical Solutions Group shares are held by institutional investors. Comparatively, 22.4% of Tristel shares are held by institutional investors. 4.0% of Advanced Medical Solutions Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Advanced Medical Solutions Group presently has a consensus price target of GBX 278.33, suggesting a potential downside of 1.65%. Given Advanced Medical Solutions Group's stronger consensus rating and higher possible upside, equities analysts clearly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Tristel has a net margin of 15.62% compared to Advanced Medical Solutions Group's net margin of 1.58%. Tristel's return on equity of 23.05% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group1.58% 1.44% 2.35%
Tristel 15.62%23.05%9.89%

Advanced Medical Solutions Group pays an annual dividend of GBX 2.86 per share and has a dividend yield of 1.0%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. Advanced Medical Solutions Group pays out 173.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Tristel had 7 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 8 mentions for Tristel and 1 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.78 beat Tristel's score of 0.51 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Advanced Medical Solutions Group
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tristel
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Advanced Medical Solutions Group has a beta of 0.753, indicating that its share price is 25% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market.

Summary

Tristel beats Advanced Medical Solutions Group on 10 of the 18 factors compared between the two stocks.

How does Tristel compare to NIOX Group?

Tristel (LON:TSTL) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£51.12M3.75£6.54M£16.2424.56
NIOX Group£47.50M6.10£995.88M£1.6342.21

Tristel has a net margin of 15.62% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.05% beat NIOX Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.62% 23.05% 9.89%
NIOX Group 14.74%10.01%3.95%

In the previous week, Tristel had 6 more articles in the media than NIOX Group. MarketBeat recorded 8 mentions for Tristel and 2 mentions for NIOX Group. Tristel's average media sentiment score of 0.51 beat NIOX Group's score of 0.00 indicating that Tristel is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tristel
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 25.00%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.4% of Tristel shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tristel has a beta of 0.352, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.3%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Tristel beats NIOX Group on 11 of the 18 factors compared between the two stocks.

How does Tristel compare to EKF Diagnostics?

Tristel (LON:TSTL) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market.

In the previous week, Tristel had 7 more articles in the media than EKF Diagnostics. MarketBeat recorded 8 mentions for Tristel and 1 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 0.67 beat Tristel's score of 0.51 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tristel
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
EKF Diagnostics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tristel has a net margin of 15.62% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.05% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.62% 23.05% 9.89%
EKF Diagnostics 4.86%3.58%5.27%

22.4% of Tristel shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tristel has higher earnings, but lower revenue than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£51.12M3.75£6.54M£16.2424.56
EKF Diagnostics£51.35M1.97£4.68M£0.5840.69

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 48.31%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tristel and EKF Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

0.7% of INSPECS Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tristel had 8 more articles in the media than INSPECS Group. MarketBeat recorded 8 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.51 beat INSPECS Group's score of 0.00 indicating that Tristel is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Positive

Tristel has a net margin of 15.62% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.05% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
Tristel 15.62%23.05%9.89%

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.49-£4.11M-£5.34N/A
Tristel£51.12M3.75£6.54M£16.2424.56

INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market. Comparatively, Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market.

Summary

Tristel beats INSPECS Group on 11 of the 13 factors compared between the two stocks.

How does Tristel compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Tristel has a net margin of 15.62% compared to Creo Medical Group's net margin of -268.57%. Tristel's return on equity of 23.05% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group-268.57% -38.29% -20.09%
Tristel 15.62%23.05%9.89%

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 7.0% of Creo Medical Group shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M7.09-£25.04M-£5.00N/A
Tristel£51.12M3.75£6.54M£16.2424.56

In the previous week, Tristel had 8 more articles in the media than Creo Medical Group. MarketBeat recorded 8 mentions for Tristel and 0 mentions for Creo Medical Group. Tristel's average media sentiment score of 0.51 beat Creo Medical Group's score of 0.00 indicating that Tristel is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
Tristel Positive

Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Tristel has a beta of 0.352, suggesting that its share price is 65% less volatile than the broader market.

Summary

Tristel beats Creo Medical Group on 10 of the 13 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSTL vs. The Competition

Export
MetricTristelHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£196.02M£5.91B£7.57B£2.78B
Dividend Yield3.70%1.71%2.47%6.26%
P/E Ratio25.1126.44275.89366.17
Price / Sales3.8369.72563.0289,467.46
Price / Cash20.9632.9527.1027.83
Price / Book5.975.8410.506.91
Net Income£6.54M£147.49M£3.51B£5.88B
7 Day Performance0.06%-0.06%0.53%-1.33%
1 Month Performance-0.31%-4.32%-7.11%-2.14%
1 Year Performance12.08%3.68%1.66%21.05%

Tristel Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSTL
Tristel
N/AGBX 407.75
+2.2%		N/A+9.6%£196.02M£51.12M25.11208
AMS
Advanced Medical Solutions Group
0.807 of 5 stars		GBX 282.10
+0.0%		GBX 278.33
-1.3%		+27.5%£614.15M£233.63M170.9710
NIOX
NIOX Group
1.7325 of 5 stars		GBX 66.79
-1.5%		GBX 86
+28.8%		-1.1%£281.09M£47.50M40.9792
EKF
EKF Diagnostics
2.9472 of 5 stars		GBX 24.30
flat		GBX 35
+44.0%		-9.2%£104.00M£51.35M41.90356
SPEC
INSPECS Group
N/AGBX 88.50
-1.7%		N/A+56.5%£96.62M£193.23MN/A1,673

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 10/26/2026 by MarketBeat.com Staff.
From Our Partners
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...
Porter & Company | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
Forget the AI predictions. Look at the income
AI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...
Investors Alley | Sponsoredtc pixel
Finally… options made simple
Ian Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...
TradeWins | Sponsoredtc pixel
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...
Profits Run | Sponsoredtc pixel
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...
Paradigm Press | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Stanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...
Brownstone Research | Sponsoredtc pixel
80 Days Until America's Rare Earth Supply Chain Shift
China controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...
The Tomorrow Investor | Sponsoredtc pixel